A randomized, multicenter, open-label, blinded end point trial comparing the effects of spironolactone to chlorthalidone on left ventricular mass in patients with early-stage chronic kidney disease: Rationale and design of the SPIRO-CKD trial

BACKGROUND: Chronic kidney disease (CKD) is associated with increased left ventricular (LV) mass and arterial stiffness. In a previous trial, spironolactone improved these end points compared with placebo in subjects with early-stage CKD, but it is not known whether these effects were specific to th...

Descripción completa

Detalles Bibliográficos
Autores principales: Hayer, Manvir K., Edwards, Nicola C., Slinn, Gemma, Moody, William E., Steeds, Rick P., Ferro, Charles J., Price, Anna M., Andujar, Cecilio, Dutton, Mary, Webster, Rachel, Webb, David J., Semple, Scott, MacIntyre, Iain, Melville, Vanessa, Wilkinson, Ian B., Hiemstra, Thomas F., Wheeler, David C., Herrey, Anna, Grant, Margaret, Mehta, Samir, Ives, Natalie, Townend, Jonathan N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mosby 2017
Materias:
Trial Design
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5603966/
https://www.ncbi.nlm.nih.gov/pubmed/28888268
http://dx.doi.org/10.1016/j.ahj.2017.05.008

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5603966/
https://www.ncbi.nlm.nih.gov/pubmed/28888268
http://dx.doi.org/10.1016/j.ahj.2017.05.008

Ejemplares similares